arbaclofen

Arbaclofen is the R-enantiomer of baclofen, a selective gamma-aminobutyric acid type B (GABA-B) receptor agonist. It exhibits significantly greater specificity and potency for the GABA-B receptor compared to the S-enantiomer and racemic baclofen. Arbaclofen has been investigated primarily as an oral extended-release formulation for reducing spasticity in multiple sclerosis, as well as for improving social function and behavior in autism spectrum disorder and fragile X syndrome. Its mechanism involves enhancing inhibitory neurotransmission by activating GABA-B receptors, which may help restore balance between excitatory and inhibitory signaling in neurological disorders[1][2][4][5][6].

Brand names

Ontinua ER

Other names

(R)-Baclofen(R)-4-Amino-3-(4-chlorophenyl)butanoic acid